Actavis Llc An Indirect Wholly Owned Sub Of Teva Pharmaceuticals
As of the edition of 20 October 2026, Actavis Llc An Indirect Wholly Owned Sub Of Teva Pharmaceuticals runs 3 drugs, 3 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 3 |
| Total | 3 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Docetaxel anhydrous | none listed | 0 |
| Pemetrexed | none listed | 7 |
| Cabazitaxel | Ended 2025 (patent) | 0 |
A route B row is one company at one target.